Oregon's Psilocybin Services Policy with Sam Chapman
Similar Posts
Using Mycelium for a Sustainable Future feat. Kimberly Carlson
Join David in this engaging episode as he converses with Kimberly Carlson, CEO & CFO of Mushrooms Inc., a pioneering company at the forefront of driving sustainable practices through innovative mycelium applications.
The Joy of Cooking with ‘Shrooms: Making Psilocybin More Palatable
Virgina Haze, the co-author of “The Psilocybin Chef Cookbook,” promises a psychedelic experience “can be delicious as well as trippy.”
Top 5 Psychedelics Milestones In 2021 & What To Expect in 2022 | Science, Funding, Stocks & More
The psychedelic medicines industry had a revolutionary year in 2021. At the start of the year, there were only a couple of publicly traded companies, but by the end of it, there were dozens. These companies are racing to answer questions such as: Can psychedelics cure depression? Can psychedelic treat anxiety? And, can psychedelics help with mental health?
Though the answers to these questions have not been proven 100%, after 2021, it does appear more likely than not that the answer to some of these at least, is yes. In this video, we will recap some of the most significant milestones of the psychedelics industry in 2021, and end it with what I am looking forward to in the new year.
The first big story of 2021 was the IPOs. Though MindMed (MNMD/MMED) and Compass Pathways (CMPS) went public in 2020, companies such as Field Trip Health (FTRP), Numinus Wellness (NUMI), atai Life Sciences (atai), Cybin Corp (CYBN), and dozens of others joined them in 2021. Add to this the launch of ETFs such as the Horizons Psychedelics ETF (PSYK) and the Advisor Shares Psychedelics ETF (PSIL), and 2021 was a huge year for the advent of public companies in the psychedelic medicines space.
The next big story was uplistings. Not all stock markets are created equal. In order to have the prestigious needed to attract serious money, companies need to be on exchanges such as the Nasdaq, NYSE, and the TSX. In 2021 we saw MindMed, Numinus, Field Trip, Cybin, and more join the big boys league.
Third, was funding. Psychedelic companies are for the most part biotech companies. In order to get a new drug through the clinical trial process, it takes hundreds of millions of dollars. This year we saw atai, Compass, MindMed, Cybin, and Field Trip, among others, raise over a billion dollars for the industry. This will sustain them for years to come.
And finally, 2021 saw a few high-profile clinical trials. The most significant was the MAPS Phase 3 clinical trial, which treated PTSD with MDMA-assisted therapy. The results of this trial were earth-shattering. Equally important was the Compass phase 2b trial, treating treatment-resistant depression with Psilocybin.
Moving into the new year, I am excited to see more clinical trials, and I expect to see mergers in the field.
Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com
Music from:
www.bensound.com
Video editing: @themyaholy
@Psychedelic Spotlight
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.
All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.
#Psychedelics #MindMed #Psylocybin
California Senate Votes in Favor of Legalizing Natural Psychedelics
SB-58 would legalize the personal use of certain amounts of psilocybin, psilocyn, DMT, ibogaine, and mescaline.
Psilocybin Pre-Workout Stacks: Can Mushrooms Improve Your Urge To Move?
A psilocybin pre-workout stack might offer you an alternate way to form a bond between both your body and mind, get more out of your workouts, perform better and faster recoveries—especially if it is coupled with some nutritious superfoods.
![Investing in Psychedelic Stocks 101 [ Interview With The Medicine Of Being Human]](https://psychedelicspotlight.com/wp-content/uploads/2022/06/maxresdefault-34-600x338.jpeg)
Investing in Psychedelic Stocks 101 [ Interview With The Medicine Of Being Human]
Hello Psychedelic Investors! As I mentioned in the previous episode of the Psychedelic Investor, last week I had my first ever interview with the wonderful Sena who is interested in creating a resource for those new to investing in psychedelic stocks and investing in stocks in general.
For those interested in the basics on psychedelic investing, you can watch the entire video on:
The Medicine of Being Human :https://www.youtube.com/watch?v=p3d_t4GYG14&t=599s&ab_channel=TheMedicineofBeingHuman
#PsychedelicStocks #MindMed #ThePsychedelicInvestor
I hope you guys found some value in this and I’ll keep you posted for more changes!
Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.